Panitumumab-Induced Periorbital Dermatitis: A Case Report

References

• Hocking CM, Townsend AR, Price TJ. Panitumumab in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2013;13(7):781–793. doi:10.1586/14737140.2013.811064
   PubMed Web of Science ®Google Scholar
• Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007;22(1 Suppl 4):S24–S39. doi:10.1177/17246008070221s404
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425–1433. doi:10.1093/annonc/mdi279
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Pongcharoen P, Vachiramon V. Cutaneous adverse events of epidermal growth factor receptor inhibitors: a retrospective review of 99 cases. Indian J Dermatol Venereol Leprol. 2015;81(5):547. doi:10.4103/0378-6323.157448
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract. 2014;2014:734249. doi:10.1155/2014/734249
   PubMedGoogle Scholar
• National Cancer Institute Database. Rockville: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; 2017. Available from: https://www.cancer.gov. Accessed March 3, 2024
   Google Scholar
• Li Y, Fu R, Jiang T, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022;12:804212. doi:10.3389/fonc.2022.804212
   PubMed Web of Science ®Google Scholar
• Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4):1167–1174. doi:10.1007/s00520-012-1645-y
   PubMed Web of Science ®Google Scholar
• Chan JYY, Kwok TYT, Yuen HKL. Eyelash trichomegaly induced by erlotinib for metastatic lung cancer. Hong Kong Med J. 2021;27(1):60.e1–60.e3. doi:10.12809/hkmj208506
   Web of Science ®Google Scholar
• Jin HD, Blessing NW. Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer. Am J Ophthalmol Case Rep. 2020;19:100810. doi:10.1016/j.ajoc.2020.100810
   PubMedGoogle Scholar
• Manthri S, Chakraborty K. Blepharitis: a rare side effect related to cetuximab in patient with colorectal cancer. BMJ Case Rep. 2019;12(8):e231774. doi:10.1136/bcr-2019-231774
   PubMedGoogle Scholar
• Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care. 2007;16(5):439–443. doi:10.1111/j.1365-2354.2006.00763.x
   PubMed Web of Science ®Google Scholar
• Scofield-Kaplan S, Todaro J, Winn BJ. Reversible cicatricial ectropion associated with EGFR inhibitors. Orbit. 2018;37(5):364–367. doi:10.1080/01676830.2017.1423342
   PubMed Web of Science ®Google Scholar
• Frankfort BJ, Garibaldi DC. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling. Ophthalmic Plast Reconstr Surg. 2007;23(6):496–497. doi:10.1097/IOP.0b013e31815a124b
   PubMed Web of Science ®Google Scholar
• Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthalmic Plast Reconstr Surg. 2007;23(1):63–65. doi:10.1097/IOP.0b013e31802d97f0
   PubMed Web of Science ®Google Scholar
• Lee MS, Kopetz S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14(4):203–218. doi:10.1016/j.clcc.2015.05.006
   PubMed Web of Science ®Google Scholar
• Battaglin F, Dadduzio V, Bergamo F, et al. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opin Biol Ther. 2017;17(10):1297–1308. doi:10.1080/14712598.2017.1356815
   PubMed Web of Science ®Google Scholar
• Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer. 2011;10(4):333–339. doi:10.1016/j.clcc.2011.06.004
   PubMed Web of Science ®Google Scholar
• Goyal A, Blaes A. Trichomegaly associated with panitumumab. N Engl J Med. 2020;383(16):e94. doi:10.1056/NEJMicm2003622
   PubMed Web of Science ®Google Scholar
• Goyal S, Uwaydat SH. Epidermal growth factor receptor inhibitor induced trichomegaly and poliosis. Ophthalmology. 2018;125(2):294. doi:10.1016/j.ophtha.2017.11.004
   PubMed Web of Science ®Google Scholar
• Sarzi Sartori D, Larangeira de Almeida A, Santana Pereira de Oliveira G, de Almeida HL. Scanning electron microscopy of panitumumab-induced eyelash and hair alterations - Pili canaliculi. An Bras Dermatol. 2022;97(2):240–242. doi:10.1016/j.abd.2021.03.011
   PubMed Web of Science ®Google Scholar
• Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798–1802. doi:10.1016/j.ophtha.2012.03.002
   PubMed Web of Science ®Google Scholar
• Wolf R, Orion E, Tüzün Y. Periorbital (eyelid) dermatides. Clin Dermatol. 2014;32(1):131–140. doi:10.1016/j.clindermatol.2013.05.035
   PubMed Web of Science ®Google Scholar
• Mughal AA, Kalavala M. Contact dermatitis to ophthalmic solutions. Clin Exp Dermatol. 2012;37(6):593–597. doi:10.1111/j.1365-2230.2012.04398.x
   PubMed Web of Science ®Google Scholar
• Landeck L, John SM, Geier J. Periorbital dermatitis in 4779 patients - patch test results during a 10-year period. Contact Dermatitis. 2014;70(4):205–212. doi:10.1111/cod.12157
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013;8(3):173–181. doi:10.1007/s11523-013-0257-x
   PubMed Web of Science ®Google Scholar